Figure 6 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Year: 2024
Type: other
Abstract: KD of TDO2 reduces TNBC cell invasion except when IDO1 increases in a compensatory manner, and pharmacologic inhibition of TDO2/IDO1 reduces invasion and is synergistic with AhR inhibition. A, Invasion assay of scramble control (shSCR) or TDO2-KD (shTDO2) BT549. B, Invasion assays following pretreatment and maintaining with 10 µmol/L AT-0174, 10 µmol/L AhR inhibitor StemRegenin, or combination on BT549 shTDO2-98 (IDO1 comp) cells. C, BT549 cells under attached and suspension conditions were treated with 10 µmol/L of AT-0174 or StemRegenin. D, BT549 cells were treated with or without 10 µmol/L KYN in combination with 10 µmol/L AT-0174 and 10 µmol/L StemRegenin. E, Invasion inhibition (%) of BT549 cells treated with three doses (0.1, 1, and 10 µmol/L) of AT-0174, StemRegenin, or combination. Synergy score was calculated using SynergyFinder with the input of invasion inhibition. F, TDO2 and IDO1 protein expression in TNBC cell lines. G, MDA-MB-231 cells were treated with vehicle (DMSO) control, 10 µmol/L AT-0174, 10 µmol/L StemRegenin, 10 µmol/L epacadostat, or combination. All treatments were conducted for 48 hours, and the invasion through Cultrex was assayed by transwell for 24 hours. Invaded cells were stained with 0.5%/25% (v/v) crystal violet/methanol, dissolved in 10% acetic acid, and absorbance was measured. Data are displayed as mean ± SD with t test or one-way ANOVA analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403467668